Posttransfusion hepatitis in acute myelogenous leukemia. Effect on survival

Related Experiment Videos

K A Foon, C Yale, K Clodfelter

|October 17, 1980

Abstract:

We evaluated retrospectively the clinical outcome of 47 patients with acute myelogenous leukemia who entered an intensive chemoimmunotherapy treatment protocol between January 1975 and July 1978. Remission duration and survival were substantially longer in patients in whom hepatitis developed.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Changing paradigms in the treatment of chronic lymphocytic leukemia.

Leukemia·2009

Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma.

Molecular imaging and biology·2008

Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706.

Leukemia·2005

Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer.

Clinical breast cancer·2002

Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression.

Molecular therapy : the journal of the American Society of Gene Therapy·2001

Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu.

International journal of cancer·2001

See all related articles